Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial

• Main Authors: Binghe Xu (Author), Qingyuan Zhang (Author), Xichun Hu (Author), Qing Li (Author), Tao Sun (Author), Wei Li (Author), Quchang Ouyang (Author), Jingfen Wang (Author), Zhongsheng Tong (Author), Min Yan (Author), Huiping Li (Author), Xiaohua Zeng (Author), Changping Shan (Author), Xian Wang (Author), Xi Yan (Author), Jian Zhang (Author), Yue Zhang (Author), Jiani Wang (Author), Liang Zhang (Author), Ying Lin (Author), Jifeng Feng (Author), Qianjun Chen (Author), Jian Huang (Author), Lu Zhang (Author), Lisong Yang (Author), Ying Tian (Author), Hongyan Shang (Author)
• Format: Book
• Published: Elsevier, 2023-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

Entinostat plus exemestane in hormone receptor-positive (HR+) advanced breast cancer (ABC) previously showed encouraging outcomes. This multicenter phase 3 trial evaluated the efficacy and safety of entinostat plus exemestane in Chinese patients with HR + ABC that relapsed/progressed after ≥1 endocrine therapy. Patients were randomized (2:1) to oral exemestane 25 mg/day plus entinostat (n = 235) or placebo (n = 119) 5 mg/week in 28-day cycles. The primary endpoint was the independent radiographic committee (IRC)-assessed progression-free survival (PFS). The median age was 52 (range, 28-75) years and 222 (62.7%) patients were postmenopausal. CDK4/6 inhibitors and fulvestrant were previously used in 23 (6.5%) and 92 (26.0%) patients, respectively. The baseline characteristics were comparable between the entinostat and placebo groups. The median PFS was 6.32 (95% CI, 5.30-9.11) and 3.72 (95% CI, 1.91-5.49) months in the entinostat and placebo groups (HR, 0.76; 95% CI, 0.58-0.98; P = 0.046), respectively. Grade ≥3 adverse events (AEs) occurred in 154 (65.5%) patients in the entinostat group versus 23 (19.3%) in the placebo group, and the most common grade ≥3 treatment-related AEs were neutropenia [103 (43.8%)], thrombocytopenia [20 (8.5%)], and leucopenia [15 (6.4%)]. Entinostat plus exemestane significantly improved PFS compared with exemestane, with generally manageable toxicities in HR + ABC (ClinicalTrials.gov #NCT03538171).

Item Description

2211-3835
10.1016/j.apsb.2023.02.001